bioRxivCell BiologyPreprint
The finger 2 tip loop of Activin A is required for the formation of its non-signaling complex with ACVR1 and type II Bone Morphogenetic Protein receptors
S. Aykul, R. A. Corpina, E. J. Goebel, C. J. Cunanan, A. Dimitriou, H. Kim, Q. Zhang, A. Rafique, R. Leidich, X. Wang, J. McClain, J. Jimenez, K. C. Nannuru, N. J. Rothman, J. B. Lees-Shepard, T. B. Thompson, E. Martinez-Hackert, A. J. Murphy, A. N. Economides, V. Idone
Abstract
Activin A functions in BMP signaling in two ways: it either engages ACVR1B to activate Smad2/3 signaling or binds ACVR1 to form a non-signaling complex (NSC). Although the former property has been studied extensively, the roles of the NSC remain unexplored. The genetic disorder fibrodysplasia ossificans progressiva (FOP) provides a unique window into ACVR1/Activin A signaling because in that disease Activin can either signal through FOP-mutant ACVR1 or form NSCs with wild type ACVR1. To explore the role of the NSC, we generated agonist-only Activin A muteins that activate ACVR1B but cannot form the NSC with ACVR1. Using one of these muteins we demonstrate that failure to form the NSC in FOP results in more severe disease pathology. These results provide the first evidence for a biological role for the NSC in vivo and pave the way for further exploration of the NSCs physiological role in corresponding knock-in mice. Impact StatementThe non-signaling complex formed by Activin A and ACVR1 is operant in vivo and is required to temper the degree of heterotopic ossification in the genetic disorder fibrodysplasia ossificans progressiva.
- organism: human
- research focus: host-pathogen & immune response
- research focus: differential expression
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Coordinate regulation of Activin and Bone Morphogenetic Protein signaling by a lysosomal trafficking switch
W. W. Hom, S. Aykul, … A. N. Economides·bioRxiv·Jan 29, 2024
- ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1
S. Aykul, L. Huang, … S. J. Hatsell·bioRxiv·Jul 18, 2021
- Reduced GS domain serine/threonine requirements of Fibrodysplasia Ossificans Progressiva mutant type I BMP receptor ACVR1 in the zebrafish
Robyn S. Allen, William David Jones, … Mary C. Mullins·Journal of Bone and Mineral ResearchPeer-reviewed·Jun 17, 2023
- An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva mice
John B. Lees-Shepard, Sean J. Stoessel, … David J. Goldhamer·Journal of Clinical InvestigationPeer-reviewed·May 3, 2022
- Over-expression of wild-type ACVR1 in fibrodysplasia ossificans progressiva mice rescues perinatal lethality and inhibits heterotopic ossification
Masakazu Yamamoto, Sean J. Stoessel, … David J. Goldhamer·Journal of Bone and Mineral ResearchPeer-reviewed·Dec 1, 2020
- Multi-omics reveals global signaling rewiring and identifies Activin A-induced dysregulation of FOS/Activator Protein 1 as a novel target in Fibrodysplasia ossificans progressiva
Marius Wits, Nerea Gomez-Suarez, … Gonzalo Sánchez‐Duffhues·bioRxiv·Jan 21, 2025